Linatigen Duo Tablet 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
MFDS item code 201901553 · Approved 2019.03.13
This product's status changed to Approval withdrawn on 2024.01.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to assist in the blood sugar control of adults with type 2 diabetes. It is administered when adequate blood sugar control is not achievable with diet and exercise alone. Additionally, it is used when blood sugar control is insufficient with monotherapy of metformin or combination therapy with other medications. It can enhance therapeutic efficacy when used in conjunction with insulin or other hypoglycemic agents. This medication helps improve blood sugar control by complementing various therapeutic stages.
The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment experience in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily; it may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medication should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).
This medication contains metformin hydrochloride and linagliptin and is used for the treatment of type 2 diabetes. This medication can cause a rare but very serious complication known as lactic acidosis, and should not be administered to patients with severely impaired kidney function or those with acute infections, heart failure, or liver function disorders. Moreover, it should be avoided in women who are pregnant or nursing, as well as in patients with poor nutritional status or alcohol dependence. If taken with sulfonylureas or insulin, there may be an increased risk of hypoglycemia, so blood sugar levels should be monitored closely, and dosage adjustments of other medications may be necessary. Regular monitoring of kidney function is required while on this medication, especially in the elderly or those with mildly impaired kidney function. If iodine-containing contrast agents are used during radiological examinations, the medication should be temporarily discontinued before and after the administration of the contrast agent, and resumed only after kidney function has normalized. Patients scheduled for surgery should also stop taking this medication 48 hours beforehand and resume only after recovery from surgery. While taking this medication, rare side effects such as acute pancreatitis, severe joint pain, or skin blisters resembling bullous pemphigoid may occur, and if these symptoms appear, the physician should be notified immediately. Long-term use may lead to vitamin B12 deficiency; therefore, if anemia or neurological symptoms appear, B12 levels should be checked and supplemented as needed. This medication has relatively few drug interactions; however, when taken with certain antihypertensives, diuretics, or NSAIDs, there is a risk of kidney function deterioration, necessitating periodic monitoring. Women who are pregnant or planning to become pregnant should avoid this medication, and insulin therapy is recommended for blood sugar control. Safety and efficacy in pediatric populations have not yet been established, and in the elderly, the minimum dosage should be considered while regularly checking kidney function. In case of overdose, there is a risk of lactic acidosis, requiring immediate hospital treatment, which may include hemodialysis. This medication should be stored in a cool place away from moisture and kept out of reach of children.
Lactate acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased vitamin B12 and deficiency, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, formation of oral ulcers, abnormal liver function tests, hepatitis, itching, erythema, rash, dermatitis herpetiformis, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, epigastric pain, enterocolitis, bowel obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, constipation, epigastric pain, dyspepsia, burning mouth syndrome, colitis, abdominal discomfort, dysphagia, gastric ulcer, gum bleeding, bowel obstruction, tooth loss, hemorrhoids, acute pyelonephritis, pilar cyst, rhinitis, soft tissue infection, pharyngitis, scrub typhus, periodontitis, tonsillitis, laryngitis, viral upper respiratory infection, pneumonia, tonsillitis, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, chest discomfort, asthenia, pain, nosebleed, oropharyngeal pain, speech impairment, epistaxis, wet cough, runny nose, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase activity, increased ALT, androgenic alopecia, hyperhidrosis, hair loss, dermatitis, anxiety, insomnia, depression, hypertension, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, periodontitis, influenza, folliculitis, gingivitis, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, confusion state, nocturia, dermatitis, hypertension
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This will help preserve the medication's efficacy and safety for an extended period.
Pink, biconvex, oval film-coated tablet
30 tablets/bottle, 30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.